About this trial
Myeloproliferative neoplasms (MPNs) are caused by defects in blood cell production. This leads to an overproduction of mature cells, such as red blood cells or platelets. As a result, clinical symptoms and complications can develop. Circulatory disorders and resulting pain symptoms, such as headaches, are the most prominent. Furthermore, blood clotting disorders can occur, leading to vascular occlusions or bleeding. Over a longer period, bone marrow transformation into fibrous tissue or the development of acute leukemia can occur, resulting in even more serious complications.
In the vast majority of cases, MPNs are diagnosed in older adults. These diagnoses are extremely rare in children and adolescents. Therefore, clinical and genetic characteristics, treatment options, and outcomes in pediatric patients with MPNs are insufficiently described, and only limited data are available for standardizing diagnostic and therapeutic approaches for MPNs in childhood and adolescence. Recommendations and guidelines from the adult field, which have largely been adopted and applied to children and adolescents, do not adequately address the specific needs of patients in childhood and adolescence. To gain more insights into MPN during this early, vulnerable phase of life, we have established a nationwide registry in Germany that systematically collects data from children and adolescents with MPN.
The registry focuses particularly on the scientific analysis of the biological characteristics and differences of MPN in children and adolescents compared to adults.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Newly diagnosed PV, ET, PMF or pHES
Age < 18 years (up to 17 years and 365 days) at the day of diagnosis
Patient treated in a participating center
Written informed consent to registry participation
Disqualifiers
None
Trial population
Children and adolescents below the age of 18 years diagnosed with Myeloproliferative Neoplasms
Trial design
Cohort
Other
Treatments tested in this trial
Observation
Other interventionObservation
Treatment groups
Trial outcomes
Primary outcomes
Incidence and epidemiology
Incidence and epidemiology of PV, ET, PMF and pHES in children and adolescents through systematic inclusion of these patients in a national population-based registry
Characterization
Characterization of clinical, hematologic, genetic and cytogenetic features of children and adolescents with PV, ET, PMF and pHES
Risk identification
Identification of pediatric patients with high risk of complications and disease progression and transformation into acute myeloid leukemia (AML)
Improvement of therapy
Improvement of the therapy for children and adolescents with MPN by discussing treatment options with the treating centers and tailor therapy to the specific and individual needs of pediatric patients
Secondary outcomes
Preparation of international studies
Preparation of future international collaborative prospective studies focusing on the optimization and standardization of childhood MPN-diagnosis and treatment
Development of a biobank
Development of a biobank system of pediatric patients with MPN
Sponsors and contacts
Click on the lead sponsor to view all of their trials.